GATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis. February 25, 2025 Change of the guards-Looking back at Michael ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Treatment Options for Bladder Cancer: Bringing Life to Years of Sparse Options - Guru Sonpavde ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA was host to a session on the current state and future directions of ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA was host to a session on the current state and future directions of ...

Intermittent (“in and out”) catheterization for incomplete bladder emptying External condom catheter for men with urinary incontinence Absorbent pads and products for men and women with urinary ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA was host to a renal cell cancer oral abstract session. Dr. Kathryn E.

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Devaki Surasi discussing combination sequencing for PSMA-based therapy in advanced disease.

Historically, the recommended management for biochemically recurrent prostate cancer patients following maximal pelvic therapy with no metastasis on conventional imaging has been disease monitoring, ...

(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a plenary session on personalized approaches in high-risk and metastatic prostate cancer, and a state of the art ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Wolfgang P. Fendler discussing prostate cancer risk groups by PSMA-PET PROMISE results from ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of ...